654 related articles for article (PubMed ID: 16598769)
1. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
3. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.
Culig Z; Steiner H; Bartsch G; Hobisch A
Endocr Relat Cancer; 2005 Jun; 12(2):229-44. PubMed ID: 15947099
[TBL] [Abstract][Full Text] [Related]
5. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
6. Collocation of androgen receptor gene mutations in prostate cancer.
Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
[TBL] [Abstract][Full Text] [Related]
7. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Agoulnik IU; Weigel NL
J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
[TBL] [Abstract][Full Text] [Related]
9. The role of the androgen receptor in the development and progression of prostate cancer.
Jenster G
Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation increases p300 expression in prostate cancer cells.
Heemers HV; Sebo TJ; Debes JD; Regan KM; Raclaw KA; Murphy LM; Hobisch A; Culig Z; Tindall DJ
Cancer Res; 2007 Apr; 67(7):3422-30. PubMed ID: 17409453
[TBL] [Abstract][Full Text] [Related]
11. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
[TBL] [Abstract][Full Text] [Related]
12. Molecular regulation of androgen action in prostate cancer.
Dehm SM; Tindall DJ
J Cell Biochem; 2006 Oct; 99(2):333-44. PubMed ID: 16518832
[TBL] [Abstract][Full Text] [Related]
13. Hormone treatment for prostate cancer: current issues and future directions.
Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
[TBL] [Abstract][Full Text] [Related]
14. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
Linja MJ; Savinainen KJ; Saramäki OR; Tammela TL; Vessella RL; Visakorpi T
Cancer Res; 2001 May; 61(9):3550-5. PubMed ID: 11325816
[TBL] [Abstract][Full Text] [Related]
15. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics.
Chen G; Wang X; Zhang S; Lu Y; Sun Y; Zhang J; Li Z; Lu J
Prostate; 2005 Jun; 63(4):395-406. PubMed ID: 15617028
[TBL] [Abstract][Full Text] [Related]
18. Evolution of the androgen receptor pathway during progression of prostate cancer.
Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
[TBL] [Abstract][Full Text] [Related]
19. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
Dehm SM; Regan KM; Schmidt LJ; Tindall DJ
Cancer Res; 2007 Oct; 67(20):10067-77. PubMed ID: 17942941
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]